FDA approves apitegromab, a myostatin inhibitor, for spinal muscular atrophy

The Food and Drug Administration has approved apitegromab, an antibody that works on muscle rather than on the genetic defect behind spinal muscular atrophy (SMA). The approval was recorded in the agency's Drugs@FDA database on 11 September 2026 under biologics licence application 761463, held by Scholar Rock and cleared through the agency's priority-review track [s2]. The product, brand name Isembyld, is an injectable solution of 150 mg per 3 mL (50 mg/mL) [s2].

Apitegromab is a fully human monoclonal antibody that selectively blocks the activation of myostatin, a protein that limits muscle growth [s1]. That mechanism is deliberately different from the two SMA treatments already in wide use. Nusinersen and risdiplam both raise levels of the SMN protein that patients with SMA cannot make in sufficient quantity; apitegromab does nothing to SMN and instead tries to strengthen the muscle those drugs are meant to preserve. It is designed as an add-on, not a replacement.

What the pivotal trial tested

The approval rests on SAPPHIRE, a phase 3, double-blind, placebo-controlled trial run at 48 hospitals across nine countries, including the United States, and published in The Lancet Neurology [s1]. It enrolled 188 patients aged 2 to 21 years with genetically confirmed, nonambulatory type 2 or type 3 SMA, all of whom were already receiving nusinersen or risdiplam — at least 10 months of the former or 6 months of the latter at screening [s1]. Of those, 128 received apitegromab and 60 received placebo, given by infusion every four weeks [s1].

The trial's main test was the change at 12 months in the Hammersmith Functional Motor Scale-Expanded (HFMSE), a graded measure of motor tasks, assessed in the 2-to-12-year-old group [s1]. That is the endpoint the approval turns on, and it is worth reading closely.

What it found

Pooling both apitegromab doses (10 mg/kg and 20 mg/kg), the drug beat placebo by a least-squares mean of 1.8 HFMSE points (95% confidence interval 0.30 to 3.32; p=0.019) in children aged 2 to 12 [s1]. In absolute terms the treated children edged up by 0.6 points while the placebo group slipped by 1.2 [s1].

The single-dose comparison the trial also prespecified was weaker. Apitegromab 20 mg/kg on its own separated from placebo by 1.4 points (95% CI −0.34 to 3.13; p=0.11) — a difference that did not reach statistical significance [s1]. In other words, the positive result depended on combining the two doses, and the higher dose alone did not clear the bar. That is the central caution in reading this approval: the effect is real but modest, and its statistical strength is not uniform across the analyses the investigators ran.

On safety, the trial reported similar rates of adverse events between arms [s1]. The most common were pyrexia (26% on apitegromab versus 28% on placebo), nasopharyngitis, cough, vomiting, upper respiratory tract infection and headache — a profile the authors described as consistent with SMA and its background treatment [s1]. No patient stopped the drug because of an adverse event [s1].

How to read it

A 1.8-point gain on a scale that runs to 66 is small, and the honest framing is that apitegromab adds an increment on top of SMN-directed therapy rather than transforming it. Whether that increment is meaningful in daily life — holding a posture, using the arms, resisting the slow decline the disease still imposes — is a judgement families and neurologists will make case by case. The trial ran for 12 months, so it speaks to a year of treatment and cannot yet answer how the drug behaves over the many years SMA is actually managed [s1].

What is genuinely new is the target. The SMA drugs already in wide use raise the missing SMN protein; apitegromab instead works downstream on the muscle itself, blocking myostatin activation, and is built to sit on top of an SMN therapy rather than replace it [s1]. The same anti-myostatin logic is being explored in other muscle-wasting settings, which is why this approval is watched beyond the SMA community.

What to watch

The near-term questions are practical: which patients the prescribing information covers, where the drug sits alongside nusinersen and risdiplam, and whether real-world use reproduces even the modest trial effect. Longer trials and open-label extensions will decide whether the motor benefit holds or grows with time [s1].

This article describes research and regulatory news and is not medical advice. Decisions about SMA treatment are for patients, families and their treating clinicians.

Sources

• Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial — The Lancet Neurology, 1 September 2025
• Drugs@FDA: Isembyld (apitegromab-mstn), BLA 761463 — approval record — U.S. Food and Drug Administration, approved 11 September 2026